 acelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) reports financial results for the first quarter ended on march 31, 2016. 
 we report net loss of $11 million or $0.24 basic net loss per share as compared to net loss of $10 million or $0.23 basic net loss per share for the first quarter of 2015. during the first quarter of 2016, we made significant progress in the development of our product candidates ARX-04, sufentanil sublingual tablet, 30 micrograms, and Zalviso, sufentanil sublingual system, including the initiation of two new clinical studies. 
 the first study is an open-label clinical study for moderate to severe acute pain associated with trauma or injury and the second study is an open-label study for moderate to severe acute pain following a surgical procedure.    
 we also made progress in the development of our licensed products in the first quarter of 2016, including the launch of zalviso in the first quarter of 2016 in the european market.    
 we also made significant progress in the development of our products in the first quarter of 2016 in the form of